Using latent class analysis to identify patterns of hepatitis C service provision in drug-free treatment programs in the U.S.

Drug and Alcohol Dependence

Volumn 83, Issue 1, 2006, Pages 15-24

  Strauss, Shiela M ^a   Rindskopf, David M ^b   Astone Twerell, Janetta M ^a   Des Jarlais, Don C ^c   Hagan, Holly ^a  

^a NATIONAL DEVELOPMENT AND RESEARCH INSTITUTES   (United States)

^b CITY UNIVERSITY OF NEW YORK   (United States)

^c BETH ISRAEL MEDICAL CENTER   (United States)

Author keywords

Health services; Hepatitis C; Latent class analysis; Substance abuse treatment; U.S.

Indexed keywords

ARTICLE; HEALTH SERVICE; HEPATITIS C; HUMAN; INJECTION; MEDICAL CARE; OUTPATIENT; POLICY; PRIORITY JOURNAL; UNITED STATES;

CASE MANAGEMENT; COMORBIDITY; COMPREHENSIVE HEALTH CARE; CROSS-SECTIONAL STUDIES; DATA INTERPRETATION, STATISTICAL; DELIVERY OF HEALTH CARE; HEALTH CARE SURVEYS; HEALTH SERVICES ACCESSIBILITY; HEALTH SERVICES NEEDS AND DEMAND; HEPATITIS C; HUMANS; MODELS, STATISTICAL; PATIENT ADMISSION; REFERRAL AND CONSULTATION; STREET DRUGS; SUBSTANCE ABUSE TREATMENT CENTERS; SUBSTANCE ABUSE, INTRAVENOUS; UNITED STATES;

HEPATITIS C VIRUS;

EID: 33646171527     PISSN: 03768716     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2005.10.005     Document Type: Article

References (55)

1. Alter M.J., Kruszon-Moran D., Nainan O.V., McQuillan G.M., Gao F., Moyer L.A., Kaslow R.A., and Margolis H.S. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N. Engl. J. Med. 341 (1999) 556-562
2. Astone J., Strauss S.M., Vassilev Z.P., and Des Jarlais D.C. Provision of hepatitis C education in a nationwide sample of drug treatment programs. J. Drug Educ. 33 (2003) 107-117
3. Backmund M., Meyer K., Von Zielonka M., and Eichenlaub D. Treatment of hepatitis C infection in injection drug users. Hepatology 34 (2001) 188-193
4. Baker D. Pegylated interferon plus ribavirin for the treatment of chronic hepatitis C. Rev. Gastroenterol. Disord. 3 (2003) 93-109
5. Balogun M.A., Laurichesse H., Ramsay M.E., Sellwood J., Westmoreland D., Paver W.K., Pugh S.F., Zuckerman M., Pillay D., and Wreghitt T. Risk factors, clinical features and genotype distribution of diagnosed hepatitis C virus infections: a pilot for a sentinel laboratory-based surveillance. Commun. Dis. Public Health 6 (2003) 34-39
6. Best D., Noble A., Finch E., Gossop M., Sidwell C., and Strang J. Accuracy of perceptions of hepatitis B and C status: cross sectional investigation of opiate addicts in treatment. Br. Med. J. 319 (1999) 290-291
7. Chitwood D.D., McBride D.C., French M.T., and Comerford M. Health care need and utilization: a preliminary comparison of injection drug users, other illicit drug users, and non-users. Subst. Use Misuse 34 (1999) 727-746
8. Conway B., Prasad J., Reynolds R., Farley J., Jones M., Jutha S., Smith N., Mead A., and DeVlaming S. Directly observed therapy for the management of HIV-infected patients in a methadone program. Clin. Infect. Dis. 38 Suppl. 5 (2004) S402-S408
9. Cuffel B.J., Heithoff K.A., and Lawson W. Correlates of patterns of substance abuse among patients with schizophrenia. Hosp. Community Psychiatry 44 (1993) 247-251
10. Dalgard O., Bjoro K., Hellum K., Myrvang B., Skaug K., Gutigard B., Bell H., and Construct Group. Treatment of chronic hepatitis C in injecting drug users: 5 years' follow-up. Eur. Addict. Res. 8 (2002) 45-49
11. D'Aunno T., and Vaughn T.E. An organizational analysis of service patterns in outpatient drug abuse treatment units. J. Subst. Abuse 7 (1995) 27-42
12. D'Aunno T., Vaughn T.E., and McElroy P. An institutional analysis of HIV prevention efforts by the nation's outpatient drug abuse treatment units. J. Health Soc. Behav. 40 (1999) 175-192
13. Di Bisceglie A.M., and Hoofnagle J.H. Optimal therapy of hepatitis C. Hepatology 36 (2002) S121-S127
14. Doab A., Treloar C., and Dore G.J. Knowledge and attitudes about treatment for hepatitis C virus infection and barriers to treatment among current injection drug users in Australia. Clin. Infect. Dis. 40 (2005) S313-S320
15. Dore G.J., Law M., MacDonald M., and Kaldor J.M. Epidemiology of hepatitis C virus infection in Australia. J. Clin. Virol. 26 (2003) 171-184
16. Edlin B.R. Prevention and treatment of hepatitis C in injection drug users. Hepatology 36 Suppl. 1 (2002) S210-S219
17. Etheridge R.M., Craddock S.G., Dunteman G.H., and Hubbard R.L. Treatment services in two national studies of community-based drug abuse treatment programs. J. Subst. Abuse 7 (1995) 9-26
18. Etheridge R.M., Hubbard R.L., Anderson J., Craddock S.G., and Flynn P.M. Treatment structure and program services in the Drug Abuse Treatment Outcome Study (DATOS). Psych. Addict. Behav. 11 (1997) 244-260
19. Frank C., Mohamed M.K., Strickland G.T., Lavanchy D., Arthur R.R., Magder L.S., El Khoby T., Abdel-Wahab Y., Aly Ohn E.S., Anwar W., and Sallam I. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet 355 (2000) 887-891
20. Ghandour L.A., Martins S.S., and Chilcoat H.D. Patterns and clustering of symptoms of analgesic dependence: a latent class approach. Presentation at the 67th Annual Scientific Meeting of the College of Problems on Drug Dependence. Orlando, FL, June 21 (2005)
21. Hagan H., Thiede H., Weiss H.S., Hopkins S.G., Duchin J.S., and Alexander E.R. Sharing of drug preparation equipment as a risk factor for hepatitis C. Am. J. Public Health 91 (2001) 42-46
22. Heimer R., Clair S., Grau L.E., Bluthenthal R.N., Marshall P.A., and Singer M. Hepatitis-associated knowledge is low and risks are high among HIV-aware injection drug users in three US cities. Addiction 97 (2002) 1277-1287
23. Kwiatkowski C.F., Corsi K.F., and Booth R.E. The association between knowledge of hepatitis C virus status and risk behaviors in injection drug users. Addiction 97 (2002) 1289-1294
24. Lee M.T., Reif S., Ritter G.A., Levine H.J., and Horgan C.M. Access to services in the substance abuse treatment system. Variations by facility characteristics. Recent Dev. Alcohol 15 (2001) 137-156
25. Liang T.J., Rehermann B., Seeff L.B., and Hoofnagle J.H. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann. Intern. Med. 132 (2000) 296-305
26. Lo Y., Mendell N.R., and Rubin D.B. Testing the number of components in a normal mixture. Biometrika 88 (2001) 767-778
27. Mauss S., Berger F., Goelz J., Jacob B., and Schmutz G. A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance. Hepatology 40 (2004) 120-124
28. McCutcheon A.L. Latent Class Analysis. Quantitative Applications in the Social Sciences, Series No. 64 (1987), Sage, Thousand Oaks, CA
29. McLellan A.T., Arndt I.O., Metzger D.S., Woody G.E., and O'Brien C.P. The effects of psychosocial services in substance abuse treatment. JAMA 269 (1993) 1953-1959
30. Neri S., Bruno C.M., Abate G., Ierna D., Mauceri B., Cilio D., Bordonaro F., Pulvirenti D., Italiano C., and Caruso L. Controlled clinical trial to assess the response of recent heroin abusers with chronic hepatitis C virus infection to treatment with interferon alpha-n2b. Clin. Ther. 24 (2002) 1627-1635
31. Pratt C.-C.N.U., Paone D., Carter B.J., and Layton M.C. Hepatitis C screening and management practices: a survey of drug treatment and syringe exchange programs in New York City. Am. J. Public Health 92 (2002) 1254-1256
32. Reboussin B.A., Wolfson M., Shrestha A., and Lohman K.L. Describing patterns of underage drinking in a community sample: a latent class analysis of data from the Enforcing Underage Drinking Laws. Presentation at the 67th Annual Scientific meeting of the College of Problems on Drug Dependence. Orlando, FL, June 22 (2005)
33. Rindskopf D., and Rindskopf W. The value of latent class analysis in medical diagnosis. Stat. Med. 5 (1986) 21-27
34. Rosenblum A., Nuttbrock L., McQuistion H.L., Magura S., and Joseph H. Hepatitis C and substance use in a sample of homeless people in New York City. J. Addict. Dis. 20 (2001) 15-25
35. Schaefer M., Schmidt F., Folwaczny C., Lorenz R., Martin G., Schindlbeck N., Heldwein W., Soyka M., Grunze H., Koenig A., and Loeschke K. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology 37 (2003) 443-451
36. Seeff L.B. Natural history of hepatitis C. Am. J. Med. 107 6B (1999) 10S-15S
37. Selwyn P.A., Budner N.S., Wasserman W.C., and Arno P.S. Utilization of on-site primary care services by HIV-seropositive and seronegative drug users in a methadone maintenance program. Public Health Rep. 108 (1993) 492-500
38. Shaw L., Taylor A., Roy K.M., Cameron S.O., Burns S., Molyneaux P., McIntyre P., Codere G., and Goldberg D. Establishment of a database of diagnosed HCV-infected persons in Scotland. Commun. Dis. Public Health 6 (2003) 305-310
39. Sorensen J., and Copeland A. Drug abuse treatment as an HIV prevention strategy: a review. Drug Alcohol Depend. 59 (2000) 17-31
40. Sorensen J.L., Masson C.L., and Perlman D.C. HIV/hepatitis prevention in drug abuse treatment programs: guidance from research. Sci. Pract. Perspect. 1 (2002) 4-11
41. Stein M.D., Maksad J., and Clarke J. Hepatitis C disease among injection drug users: knowledge, perceived risk and willingness to receive treatment. Drug Alcohol Depend. 61 (2001) 211-215
42. Strauss S.M., Astone J., Vassilev Z.P., Des Jarlais D.C., and Hagan H. Gaps in the drug-free and methadone treatment program response to hepatitis C. J. Subst. Abuse Treat. 24 (2003) 291-297
43. Strauss S.M., Astone J.M., Des Jarlais D.C., and Hagan H. A comparison of HCV antibody testing in drug-free and methadone maintenance treatment programs in the United States. Drug Alcohol Depend. 73 (2004) 227-236
44. Strauss S.M., Astone J.M., Des Jarlais D.C., and Hagan H. Integrating hepatitis C services into existing HIV services: the experiences of a sample of U.S. drug treatment units. AIDS Patient Care STDS 19 (2004) 78-88
45. Strauss S.M., Astone J.M., Hagan H., and Des Jarlais D.C. The content and comprehensiveness of hepatitis C education in methadone maintenance and drug-free treatment units. J. Urban Health 81 (2004) 38-47
46. Strauss S.M., Falkin G.P., Vassilev Z., Des Jarlais D.C., and Astone J. A nationwide survey of hepatitis C services provided by drug treatment programs. J. Subst. Abuse Treat. 22 (2002) 55-62
47. Sylvestre D. Treating hepatitis C virus infection in active substance users. Clin Infect. Dis. 40 Suppl. 5 (2005) S321-S324
48. The Global Burden Of Hepatitis C Working Group. Global burden of disease (GBD) for hepatitis C. J. Clin. Pharmacol. 44 (2004) 20-29
49. Thomas D.L., Vlahov D., Solomon L., Cohn S., Taylor E., Garfein R., and Nelson K.E. Correlates of hepatitis C virus infections among injection drug users. Medicine 74 (1995) 212-220
50. Tortu S., McMahon J.M., Pouget E.R., and Hamid R. Sharing of noninjection drug-use implements as a risk factor for hepatitis C. Subst. Use Misuse 39 (2004) 211-224
51. Tortu S., Neaigus A., McMahon J., and Hagen D. Hepatitis C among non-injecting drug users: a report. Subst. Use Misuse 36 (2001) 523-534
52. Umbricht-Schneiter A., Ginn D.H., Pabst K.M., and Bigelow E. Providing medical care to methadone clinic patients: referral vs. on-site care. Am. J. Public Health 84 (1994) 207-210
53. Van Thiel D.H., Anantharaju A., and Creech S. Response to treatment of hepatitis C in individuals with a recent history of intravenous drug abuse. Am. J. Gastroenterol. 98 (2003) 2281-2288
54. Vermunt, J.K., 1997. LEM: A General Program for the Analysis of Categorical Data. User's Manual. (Tilburg University, Tilburg, The Netherlands). Available online at http://www.uvt.nl/faculteiten/fsw/organisatie/departementen/mto/software2.html. Accessed on September 23, 2005.
55. Wasley A., and Alter M.J. Epidemiology of hepatitis C: geographic differences and temporal trends. Semin. Liver Dis. 20 (2000) 1-16